HCG further plans to expand by adding 100 beds and cancer diagnostic and treatment facility within an estimated operational timeline of 2 years, demonstrating a commitment to meeting the region's healthcare demands.
The acquisition also unlocks opportunities for operational scale-up, including the introduction of organ-specific practices and the introduction of next-gen cancer care technologies.
Raj Gore, chief executive officer (CEO), Healthcare Global Enterprises, said, ?Our endeavor is to make the most advanced and comprehensive cancer treatment available to patients and provide longer and better quality of life to each patient without having to travel miles for it. We would be extending our network strength of renowned oncologists' and largest tumor board in the country to Indore and Madhya Pradesh. Patient outcome is of paramount importance to us and we ensure that all our clinical and non-clinical resources are channelized and geared towards patient care.
Dr. B. S. Ajaikumar, executive chairman, Healthcare Global Enterprises, said, ?This milestone marks our entry into this vibrant healthcare market and underscores our unwavering commitment to delivering world-class cancer care. We believe in the potential of this acquisition to make a meaningful impact on the lives of countless patients and further our mission of ensuring accessible and exceptional cancer care across India. Our team's commitment and SRJ CBCC Cancer Hospital's established tradition of excellence make us ready to revolutionize oncology care in Indore and the surrounding areas.?
HealthCare Global Enterprises largest cancer care network in India. Through its network of 21 comprehensive cancer centers across India and Africa, HCG has brought advanced cancer care to the doorstep of millions of people. HCG provides best-in-class cancer care by adopting globally acclaimed practices and state-of-the-art technology under one roof.
The company's consolidated net profit jumped 25.8% to Rs 7.61 crore on 12.9% increase in net sales to Rs 459.71 crore in Q1 FY24 over Q1 FY23.
The scrip fell 0.50% to Rs 360.80 on the BSE.
Powered by Capital Market - Live News